1070 related articles for article (PubMed ID: 29305812)
1. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
2. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
Bittner V
Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
[No Abstract] [Full Text] [Related]
4. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
6. LDL cholesterol: How low to go?
Packard CJ
Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Ortega Martínez de Victoria E
Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
[No Abstract] [Full Text] [Related]
8. Identifying Patients for Nonstatin Therapy.
Robinson JG; Watson KE
Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
[TBL] [Abstract][Full Text] [Related]
9. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
11. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
12. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
[TBL] [Abstract][Full Text] [Related]
13. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
14. Implications for REDUCE IT in clinical practice.
Bittner V
Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195
[TBL] [Abstract][Full Text] [Related]
15. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
16. Nonstatin Therapy for Dyslipidemia.
Ahmed HM; Nissen SE
Circ Res; 2018 Oct; 123(9):1036-1038. PubMed ID: 30355163
[No Abstract] [Full Text] [Related]
17. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
Handelsman Y; Lepor NE
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
[No Abstract] [Full Text] [Related]
19. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
Leong D; Wu PE
CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
[No Abstract] [Full Text] [Related]
20. The PCSK9 revolution: Current status, controversies, and future directions.
Warden BA; Fazio S; Shapiro MD
Trends Cardiovasc Med; 2020 Apr; 30(3):179-185. PubMed ID: 31151804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
